Rhinocerebral Phycomycosis in Association with Diabetic Ketoacidosis

Abstract

The relationship of ketoacidosis to invasiveness by this otherwise innocuous saprophyte is delineated. A summary of the clinical and experimental experience with amphotericin B in phycomycosis has been compiled, and supports the efficacy of this mode of therapy. A cumulative dose of at least 3 g of amphotericin B is recommended for treatment of rhinocerebral phycomycosis when it occurs in the decompensated diabetic. If renal toxicity becomes evident, therapy on alternate days may maintain the therapeutic effect of the drug while diminishing renal damage.